ReviewRegenerative medicine research2013
Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent.
Review in Regenerative medicine research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Discovery of a chemical small molecule inducing umbilical cord mesenchymal stem cell differentiation to vascular endothelial cells.Cell regeneration (London, England) · 2026Article
- VEGFR1 as a Target for Cardiovascular Gene Therapy.Journal of cardiovascular translational research · 2025Review
- Endothelial Progenitor Cells in Life, Pregnancy and Disease.Expert reviews in molecular medicine · 2025Review
- Article
- Addressing Endothelial Dysfunction in Heart Failure: The Role of Endothelial Progenitor Cells and New Treatment Horizons.Cardiac failure review · 2025Review
- Latest Advances in Endothelial Progenitor Cell-Derived Extracellular Vesicles Translation to the Clinic.Frontiers in cardiovascular medicine · 2021Review
- Vascular Remodeling in Moyamoya Angiopathy: From Peripheral Blood Mononuclear Cells to Endothelial Cells.International journal of molecular sciences · 2020Article
- Androgen action augments ischemia-induced, bone marrow progenitor cell-mediated vasculogenesis.International journal of biological sciences · 2018Article
- The Cardiovascular Effects of Cocoa Polyphenols-An Overview.Diseases (Basel, Switzerland) · 2016Review
- Engineered Biomaterials to Enhance Stem Cell-Based Cardiac Tissue Engineering and Therapy.Macromolecular bioscience · 2016Article
- Diabetic Endothelium Dysfunction, Cardiovascular Complications, and Therapeutics.Journal of diabetes research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regenerative medicine techniques to recover cardiac and vascular function are being increasingly investigated as management strategies for cardiovascular diseases. Circulating endothelial progenitor cells (EPCs) derived from bone marrow are immature cells capable of differentiating into mature endothelial cells and play a role in vascular reparative processes and neoangiogenesis. The potency of EPCs for cardiovascular regeneration has been demonstrated in many preclinical studies and therapeutic utility of EPCs has been evaluated in early-phase clinical trials. However, the regenerative activity and efficiency of the differentiation of EPCs are still limited, and a directed differentiation method for EPCs cells has not been fully demonstrated. In this review, we introduce the role of circulating EPCs as biomarkers of cardiovascular diseases and medical applications of EPCs for cardiovascular regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.